Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame	Description
Primary	The proportion of subjects achieving clinical inactive disease (CID) at Week 24, where CID is defined as the absence of Still's disease-related symptoms with normal ESR or CRP levels.	At Week 24 from initiation of treatment
Secondary	Proportion of subjects achieving afebrile status with either ≥50% reduction in CRP levels or CRP within normal range at Weeks 2, 4, and 8.	At Weeks 2, 4, and 8 after treatment initiation	Efficacy Endpoints
Secondary	Proportion of subjects achieving afebrile status with either ≥70% reduction in CRP levels or CRP within normal range at Week 12.	At Week 12 after treatment initiation	Efficacy Endpoints
Secondary	Proportion of subjects achieving afebrile status with either ≥70% reduction in CRP levels or CRP within normal range, and glucocorticoid dose ≤0.2 mg/kg/day at Week 12.	At Week 12 after treatment initiation	Efficacy Endpoints
Secondary	Proportion of subjects achieving afebrile status with either ≥70% reduction in CRP levels or CRP within normal range, and glucocorticoid dose ≤0.1 mg/kg/day at Week 12.	At Week 12 after treatment initiation	Efficacy Endpoints
Secondary	Proportion of subjects achieving clinical inactive disease (CID) with discontinuation of glucocorticoids	At Week 24 after treatment initiation	Efficacy Endpoints
Secondary	Proportion of subjects without disease relapse at Weeks 12 and 24.	At Weeks 12 and 24 after treatment initiation	Efficacy Endpoints
Secondary	ACR30, ACR50, ACR70, and ACR90 response rates at Weeks 2, 4, 8, 12, 16, 20, and 24.	At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation	Efficacy Endpoints
Secondary	Change from baseline in ferritin levels at Weeks 2, 4, 8, 12, 16, 20, and 24.	At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation	Efficacy Endpoints
Secondary	Change from baseline in cytokine levels (including sIL-2R) at Weeks 2, 4, 8, 12, 16, 20, and 24.	At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation	Efficacy Endpoints
Secondary	Change from baseline in ESR at Weeks 2, 4, 8, 12, 16, 20, and 24.	At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation	Efficacy Endpoints
Secondary	Change from baseline in CRP levels at Weeks 2, 4, 8, 12, 16, 20, and 24	At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation	Efficacy Endpoints
Secondary	Change from baseline in Pouchot score at Weeks 2, 4, 8, 12, 16, 20, and 24.	At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation	Efficacy Endpoints. Pouchot score ranges from 0 to 12 points, with higher scores indicating a poorer outcome.
Secondary	Change from baseline in glucocorticoid dose at Weeks 2, 4, 8, 12, 16, 20, and 24.	At Weeks 2, 4, 8, 12, 16, 20, and 24 after treatment initiation	Efficacy Endpoints
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Through study completion, an average of 1 year

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07191444/registered

API reference For AI assistants